Evan R. Zynda

535 total citations
12 papers, 382 citations indexed

About

Evan R. Zynda is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Evan R. Zynda has authored 12 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 5 papers in Immunology and 4 papers in Oncology. Recurrent topics in Evan R. Zynda's work include Immune Cell Function and Interaction (4 papers), CAR-T cell therapy research (3 papers) and Heat shock proteins research (3 papers). Evan R. Zynda is often cited by papers focused on Immune Cell Function and Interaction (4 papers), CAR-T cell therapy research (3 papers) and Heat shock proteins research (3 papers). Evan R. Zynda collaborates with scholars based in United States, Switzerland and Israel. Evan R. Zynda's co-authors include Elizabeth A. Repasky, Navjot Kaur, Shayne Boucher, Erica L. Heipertz, Mohan C. Vemuri, Tor Espen Stav-Noraas, Melissa Grimm, Maegan L. Capitano, Thomas A. Mace and Lingwen Zhong and has published in prestigious journals such as Cell Death and Differentiation, Frontiers in Immunology and Cell Reports.

In The Last Decade

Evan R. Zynda

11 papers receiving 374 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evan R. Zynda United States 9 184 157 127 69 28 12 382
Jawoon Yi South Korea 8 117 0.6× 48 0.3× 140 1.1× 59 0.9× 12 0.4× 12 328
Matthias Schröder Germany 12 115 0.6× 57 0.4× 154 1.2× 18 0.3× 5 0.2× 28 325
Andreas Warnecke Sweden 7 228 1.2× 62 0.4× 122 1.0× 19 0.3× 16 0.6× 8 399
Leo Boneschansker United States 9 105 0.6× 29 0.2× 75 0.6× 79 1.1× 17 0.6× 12 283
Alexis Valdovinos United States 3 250 1.4× 62 0.4× 151 1.2× 26 0.4× 14 0.5× 4 545
Nicolas Mélin Switzerland 8 59 0.3× 85 0.5× 111 0.9× 58 0.8× 10 0.4× 9 300
Xiaomin Wen China 10 75 0.4× 45 0.3× 146 1.1× 37 0.5× 38 1.4× 25 396
Lindsey Catherine Mehl United States 3 178 1.0× 41 0.3× 125 1.0× 24 0.3× 23 0.8× 3 317
Ren‐He Xu Macao 9 56 0.3× 49 0.3× 152 1.2× 30 0.4× 14 0.5× 17 301

Countries citing papers authored by Evan R. Zynda

Since Specialization
Citations

This map shows the geographic impact of Evan R. Zynda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan R. Zynda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan R. Zynda more than expected).

Fields of papers citing papers by Evan R. Zynda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan R. Zynda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan R. Zynda. The network helps show where Evan R. Zynda may publish in the future.

Co-authorship network of co-authors of Evan R. Zynda

This figure shows the co-authorship network connecting the top 25 collaborators of Evan R. Zynda. A scholar is included among the top collaborators of Evan R. Zynda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan R. Zynda. Evan R. Zynda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
2.
Heipertz, Erica L., Evan R. Zynda, Tor Espen Stav-Noraas, et al.. (2021). Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies. Frontiers in Immunology. 12. 732135–732135. 134 indexed citations
3.
Zynda, Evan R., et al.. (2019). The role of PAK1 in the sensitivity of kidney epithelial cells to ischemia-like conditions. Cell Cycle. 18(5). 596–604. 8 indexed citations
4.
Zynda, Evan R. & Pei‐Yi Lin. (2019). Optimization of a phenol red-free T cell expansion medium to improve performance and workflow flexibility. Cytotherapy. 21(5). e15–e15. 1 indexed citations
5.
Guo, Lili, Luis Gil‐de‐Gómez, Andrew Medvec, et al.. (2018). Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. Cell Reports. 23(3). 741–755. 47 indexed citations
6.
Zynda, Evan R., et al.. (2015). An RNA interference screen identifies new avenues for nephroprotection. Cell Death and Differentiation. 23(4). 608–615. 10 indexed citations
7.
Zynda, Evan R., Melissa Grimm, Min Yuan, et al.. (2015). A role for the thermal environment in defining co-stimulation requirements for CD4+T cell activation. Cell Cycle. 14(14). 2340–2354. 23 indexed citations
8.
Zynda, Evan R., et al.. (2014). Protein kinase A type II-α regulatory subunit regulates the response of prostate cancer cells to taxane treatment. Cell Cycle. 13(20). 3292–3301. 13 indexed citations
9.
Zynda, Evan R., et al.. (2013). ETV1 positively regulates transcription of tumor suppressor ARF. Cancer Biology & Therapy. 14(12). 1167–1173. 4 indexed citations
10.
Mace, Thomas A., Lingwen Zhong, Casey L. Kilpatrick, et al.. (2011). Differentiation of CD8+ T cells into effector cells is enhanced by physiological range hyperthermia. Journal of Leukocyte Biology. 90(5). 951–962. 77 indexed citations
11.
Arnouk, Hilal, Evan R. Zynda, Xiangyang Wang, et al.. (2010). Tumour secreted grp170 chaperones full-length protein substrates and induces an adaptive anti-tumour immune response in vivo. International Journal of Hyperthermia. 26(4). 366–375. 10 indexed citations
12.
Grimm, Melissa, et al.. (2009). Diverse immune mechanisms may contribute to the survival benefit seen in cancer patients receiving hyperthermia. Immunologic Research. 46(1-3). 137–154. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026